A5014857666- Lymphoma Diagnosis and Treatment
- Head and Neck Cancer Studies
- Viral-associated cancers and disorders
- Cancer Risks and Factors
- Radiopharmaceutical Chemistry and Applications
- Healthcare Policy and Management
- Head and Neck Surgical Oncology
- Primary Care and Health Outcomes
- Global Cancer Incidence and Screening
- CAR-T cell therapy research
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Peripheral Artery Disease Management
- Histiocytic Disorders and Treatments
- Chronic Lymphocytic Leukemia Research
- Renal and Vascular Pathologies
- Gestational Trophoblastic Disease Studies
- Oral health in cancer treatment
- Chronic Disease Management Strategies
- Vascular Procedures and Complications
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
Huntsman Cancer Institute
2024
University of Utah
2018-2024
Saint Louis University
2019
Princess Margaret Cancer Centre
2015
University of Toronto
2015
Princess Margaret Hospital
2014
The current study was conducted to determine whether the incidence of late-stage head and neck cancer (HNC) is decreasing estimate risk HNC diagnosis based on race sex.Age-adjusted rates for patients aged ≥18 years with stage IV were abstracted from Surveillance, Epidemiology, End Results database (2004-2015). Rates stratified by race, sex, age. Joinpoint regression estimated annual percent changes (APCs) in over time, logistic adjusted odds ratios (aORs).There 57,118 cohort, an average age...
Previous oncological studies showed that lymph node ratio (LNR) (ratio of number nodes tested positive for metastasis to the total examined) is a negative indicator cancer survival. The American Joint Committee on Cancer (AJCC) staging system incorporates tumor size, involvement, and in comprehensive model progression, but LNR alone has been shown outperform AJCC prognostic survival predictions various types cancer. effectiveness not evaluated breast staging. Evaluating predicting potential...
7570 Background: Plasmablastic Lymphoma (PBL) is a rare aggressive subtype of diffuse large B-cell lymphoma primarily affecting the immunocompromised, including those living with HIV. There no established standard care, and current survival estimates range from 8-15 months (mos). With largest previous study PBL limited to 590 patients (pts), we aimed evaluate epidemiologic characteristics, treatment patterns trends on national scale. Methods: Pts diagnosed 2010-2020 were identified in...